Literature DB >> 18451010

Implications of CATIE for mental health services researchers.

Nancy H Covell1, Molly T Finnerty, Susan M Essock.   

Abstract

The authors discuss the implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for mental health services researchers, in particular the need to monitor and change prescriber behavior to encourage informed medication selection. Given the complexity and variability of response to antipsychotic medications in CATIE, use of restricted formularies is not the answer. Rather, services researchers should collaborate with service systems to develop interventions to identify questionable prescriber practices and develop interventions to change them. The CATIE results also suggest that some quality measures for antipsychotic treatment, such as the proportion of a population taking second-generation antipsychotics, need to be revisited by researchers. Also, because the CATIE findings highlighted the prevalence of cardiac and metabolic disorders among treatment populations and the potential impact of antipsychotics on these conditions, services researchers should use secondary data to monitor whether prescribers are providing appropriate screening and treatment. Given the health risks of some antipsychotics, services researchers should develop ways to identify individuals at risk, encourage behavior change among prescribers, and support informed and shared decision making about medications. Mental health services researchers can build relationships with multiple stakeholders, including service system administrators, service providers, and consumers, to help translate results from trials such as CATIE into policy and practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451010      PMCID: PMC3739687          DOI: 10.1176/ps.2008.59.5.526

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  11 in total

1.  CATIE and the value of atypical antipsychotics in the context of creating a recovery-oriented behavioral health system.

Authors:  Mark S Salzer; Arthur C Evans
Journal:  Adm Policy Ment Health       Date:  2006-09

2.  Interpreting the results of the CATIE study.

Authors:  Jeffrey A Lieberman; John K Hsiao
Journal:  Psychiatr Serv       Date:  2006-01       Impact factor: 3.084

3.  In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?

Authors:  Daniel J Luchins
Journal:  Adm Policy Ment Health       Date:  2006-09

4.  Ethical principles for psychiatric administrators: the challenge of formularies.

Authors:  H Steven Moffic
Journal:  Psychiatr Q       Date:  2006

5.  Distress with medication side effects among persons with severe mental illness.

Authors:  Nancy H Covell; Ellen M Weissman; Bonnie Schell; Brian H McCorkle; W Thomas Summerfelt; Peter J Weiden; Susan M Essock
Journal:  Adm Policy Ment Health       Date:  2007-09

6.  Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

Authors:  Ellen M Weissman; Carolyn W Zhu; Nina R Schooler; Raymond R Goetz; Susan M Essock
Journal:  J Clin Psychiatry       Date:  2006-09       Impact factor: 4.384

Review 7.  Heterogeneity of treatment effects in schizophrenia.

Authors:  T Scott Stroup
Journal:  Am J Med       Date:  2007-04       Impact factor: 4.965

8.  Shared decision making and medication management in the recovery process.

Authors:  Patricia E Deegan; Robert E Drake
Journal:  Psychiatr Serv       Date:  2006-11       Impact factor: 3.084

9.  The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.

Authors:  Henry A Nasrallah
Journal:  J Clin Psychiatry       Date:  2007       Impact factor: 4.384

10.  Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

Authors:  Joseph P McEvoy; Jeffrey A Lieberman; T Scott Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin S Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne Severe; John K Hsiao
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 19.242

View more
  1 in total

1.  Comparative effectiveness research for antipsychotic medications: how much is enough?

Authors:  David O Meltzer; Anirban Basu; Herbert Y Meltzer
Journal:  Health Aff (Millwood)       Date:  2009-07-21       Impact factor: 6.301

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.